Handelsavisen
prelaunch
Companies Healthcare DEMANT.CO
DE
DEMANT.CO Nasdaq Copenhagen Medical Equipment, Supplies & Distribution

Demant.Co

kr286,40
Open in Charts → Attach watcher ⌖
DKK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
16,7 %
ROE
15,7 %
Net margin
6,7 %
Debt / equity
2,13
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Demant is a global leader in hearing solutions, specializing in the development, production, and distribution of hearing aids and related technologies, primarily serving the professional audiologist market.

Business. Demant is a global leader in hearing solutions, specializing in the development, production, and distribution of hearing aids and related technologies, primarily serving the professional audiologist market.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY22 analysts
13 buy8 hold1 sell
Avg 12m price target230,58

Analyst recommendations

22 analysts · consensus Buy
Buy13
Hold8
Sell1
12-month price target
230,58
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
22 analysts · indicative
Ownership
not yet wired
Profitability
15,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning DEMANT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to DEMANT.CO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Demant is a global leader in hearing solutions, specializing in the development, production, and distribution of hearing aids and related technologies, primarily serving the professional audiologist market.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Demant maintains a capital structure with a debt-to-equity ratio of 2.13, indicating a relatively high leverage position compared to industry norms. The company's liquidity is assessed as medium, with a current ratio of 1.36, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of DKK 3.234 billion supports operational flexibility, though net cash is negative after subtracting total debt, signaling potential refinancing needs.

    Profitability metrics show a return on equity (ROE) of 15.7%, which is strong relative to the industry median, while return on assets (ROA) of 3.95% is in line with sector averages. Operating income of DKK 3.832 billion and a gross profit margin of 75.6% (calculated from revenue and gross profit) reflect efficient cost management and pricing power in its core markets.

    Geographically, Demant's revenue is concentrated in Europe and North America, with a smaller but growing presence in Asia-Pacific. The company's business is segmented into two primary divisions: Demant Hearing and Demant Medical. Hearing aids constitute the majority of revenue, with the medical segment showing steady growth in surgical and diagnostic products.

    Looking ahead, revenue is projected to grow by 4.5% in the current fiscal year and 3.2% in the next, driven by market expansion in emerging economies and product innovation. Capital expenditure of DKK 652 million reflects ongoing investment in manufacturing and R&D, supporting long-term growth.

    Risk factors include liquidity constraints due to high debt levels and potential dilution from future equity offerings, though the risk of dilution is currently assessed as low. The company has not issued recent shelf or ATM registrations, and no dilutive events are imminent.

    Recent filings and transcripts highlight Demant's focus on sustainability and digital transformation, with a commitment to reducing carbon emissions and enhancing telehealth capabilities. The company also announced a new product launch in the surgical division, expected to drive incremental revenue in 2025.

    Key takeaways
    • Demant operates with a high debt-to-equity ratio, which may increase financial risk but also reflects aggressive capital deployment.
    • The company's ROE of 15.7% is a strong indicator of effective capital use and profitability.
    • Revenue is concentrated in developed markets, with growth opportunities in Asia-Pacific and emerging economies.
    • Free cash flow of DKK 3.234 billion provides flexibility for dividends, debt reduction, or strategic investments.
    • Analysts are cautiously optimistic, with a mean recommendation of 2.18 and a median price target of DKK 235.00.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    kr286,40
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    kr9.84B
    Net cash
    -kr20.99B
    Current ratio
    1.4
    Debt / equity
    2.1
    ROA
    4.0%
    ROE
    15.7%
    Cash conversion
    257.0%
    CapEx / revenue
    -2.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    12,38
    Predicted surprise
    -0,00
    Beat probability
    45 %
    Analysts
    22
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-06 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate12,38
    Revenueno estimateno estimate25,5B UNKNOWN ERROR IN UNIVERSE PROCESSING
    Operating incomeno estimateno estimate4,2B UNKNOWN ERROR IN UNIVERSE PROCESSING
    Full-year consensus mean (period as reported by source) · consensus in UNKNOWN ERROR IN UNIVERSE PROCESSING. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution22 analysts
    Strong buy6
    Buy7
    Hold8
    Sell1
    Strong sell0
    12-month price targetkr230,58 · Median kr235,00
    Low kr170,00High kr270,00
    Operating income · consensus4,2B UNKNOWN ERROR IN UNIVERSE PROCESSING
    EPS surprise
    −9,5 %
    reported vs consensus · miss
    Revenue surprise
    −9,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Lowkr170,00
    Meankr230,58
    Mediankr235,00
    Highkr270,00
    Spotkr286,40
    −19.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin16,7 %Above P75
    Net Margin6,7 %Above median
    ROE15,7 %Best in class
    Capex / Rev-2,8 %Above median
    D/E2,13Bottom quartile
    Cash Conv2,57Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • DEMANT.CO Market data — financials · 2026-05-27
    • Demant A/S Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    DEMANT.COCanonical
    Nasdaq Copenhagen · DKK

    Intel & risk

    PredictorBeat prob45 %Surprise-0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage